^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EDP1503

    i
    Other names: EDP1503, EDP 1503
    Associations

    News

    Trials
    Company:
    Evelo Biosci
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations

    News

    Trials
    4ms
    Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, University of Chicago | Suspended --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • EDP1503
    10ms
    Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=8, Suspended, University of Chicago | Trial completion date: Nov 2023 --> Nov 2027 | Trial primary completion date: Nov 2023 --> Nov 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • EDP1503
    over1year
    Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=8, Suspended, University of Chicago | Trial primary completion date: Nov 2022 --> Nov 2023
    Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • EDP1503
    over3years
    Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=8, Suspended, University of Chicago | N=70 --> 8 | Active, not recruiting --> Suspended | Trial primary completion date: Nov 2021 --> Nov 2022
    Enrollment change • Trial suspension • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • EDP1503
    over4years
    [VIRTUAL] Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity (ESMO-GI 2020)
    In a phase I/II clinical trial, the safety, tolerability, and pharmacological effects of orally administered EDP1503 in combination with pembrolizumab are being evaluated in multiple tumor types: microsatellite stable (MSS) metastatic colorectal cancer, triple-negative breast cancer, and a basket of PD-1 relapsed solid tumors. Legal entity responsible for the study The authors. Funding Evelo Biosciences.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    TILs
    |
    Keytruda (pembrolizumab) • EDP1503